Omega Funds completed the investment in Ousia Pharma.

Omega Funds, a US-based venture fund, completed the investment in Ousia Pharma, a Danish biotech company. Financial terms were not disclosed. "This investment is a strong recognition of our scientific foundation and the potential our drug candidate represents. With Omega Funds as a partner, we receive capital, strategic sparring, and global experience, which will be crucial in our further development. We are now well positioned to bring our preclinical concept to clinical testing," Anders Bue Klein, Ousia Pharma CEO.